NASDAQ:BOLT Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free BOLT Stock Alerts $1.20 0.00 (-0.02%) (As of 11:08 AM ET) Add Compare Share Share Today's Range$1.17▼$1.2150-Day Range$1.10▼$1.5052-Week Range$0.84▼$2.03Volume6,635 shsAverage Volume118,342 shsMarket Capitalization$45.76 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Bolt Biotherapeutics alerts: Email Address Bolt Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside483.3% Upside$7.00 Price TargetShort InterestBearish8.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.68) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.60 out of 5 starsMedical Sector630th out of 907 stocksPharmaceutical Preparations Industry283rd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingBolt Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.63% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.Change versus previous monthShort interest in Bolt Biotherapeutics has recently increased by 5.58%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BOLT. Previous Next 3.2 News and Social Media Coverage News SentimentBolt Biotherapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bolt Biotherapeutics this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for BOLT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows2 people have added Bolt Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders28.40% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.68) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Bolt Biotherapeutics Stock (NASDAQ:BOLT)Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Read More BOLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BOLT Stock News HeadlinesApril 25, 2024 | americanbankingnews.comBolt Biotherapeutics (NASDAQ:BOLT) Share Price Passes Above 200 Day Moving Average of $1.09April 15, 2024 | americanbankingnews.comContrasting Blueprint Medicines (NASDAQ:BPMC) & Bolt Biotherapeutics (NASDAQ:BOLT)April 25, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 22, 2024 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 21, 2024 | globenewswire.comBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateFebruary 27, 2024 | globenewswire.comBolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceJanuary 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for GlycoMimetics Amidst Phase 3 Progress and Breakthrough Therapy Designation for UproleselanDecember 5, 2023 | finance.yahoo.comBolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®April 25, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. November 11, 2023 | markets.businessinsider.comPromising Clinical Trial Results and Strong Financial Outlook Propel Buy Rating for Bolt BiotherapeuticsNovember 9, 2023 | morningstar.comBolt Biotherapeutics Inc Ordinary Shares BOLTNovember 9, 2023 | finance.yahoo.comBolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 23, 2023 | finance.yahoo.comBolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 CongressOctober 17, 2023 | finance.yahoo.comBolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced CancersSeptember 28, 2023 | finance.yahoo.comBolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric CancersSeptember 5, 2023 | finance.yahoo.comBolt Biotherapeutics to Participate in September Investor ConferencesAugust 3, 2023 | msn.comDynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass EstimatesJune 17, 2023 | finance.yahoo.comUS0977021049.SG - Bolt Biotherapeutics Inc.May 26, 2023 | markets.businessinsider.comBolt Biotherapeutics (BOLT) Receives a Buy from H.C. WainwrightMay 13, 2023 | msn.comHC Wainwright & Co. Reiterates Bolt Biotherapeutics (BOLT) Buy RecommendationMay 13, 2023 | msn.comSVB Leerink Upgrades Bolt Biotherapeutics (BOLT)May 12, 2023 | markets.businessinsider.comJonesTrading Reaffirms Their Buy Rating on Bolt Biotherapeutics (BOLT)May 12, 2023 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 26, 2023 | finance.yahoo.comBolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual MeetingApril 11, 2023 | finance.yahoo.comInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last yearMarch 30, 2023 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 14, 2023 | finance.yahoo.comBolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual MeetingSee More Headlines Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLT CUSIP09769810 CIK354655 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+488.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,200,000.00 Net Margins-878.58% Pretax Margin-878.58% Return on Equity-51.18% Return on Assets-37.81% Debt Debt-to-Equity Ratio0.15 Current Ratio5.17 Quick Ratio5.17 Sales & Book Value Annual Sales$7.88 million Price / Sales5.76 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book0.40Miscellaneous Outstanding Shares38,128,000Free Float27,300,000Market Cap$45.37 million OptionableNot Optionable Beta0.99 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Randall C. Schatzman Ph.D. (Age 69)CEO & Director Comp: $829.32kDr. Edgar George Engleman M.D. (Age 78)Founder & Independent Director Comp: $38.75kMr. William P. Quinn (Age 53)CFO & Secretary Comp: $594.56kMr. Grant Yonehiro C.F.A. (Age 60)M.B.A., Chief Business Officer Comp: $544.71kDr. Edith A. Perez M.D. (Age 67)Chief Medical Officer Comp: $668.32kMr. Wesley BurwellVP & Head of Human ResourcesDr. Nathan Ihle Ph.D.Senior Vice President of Pharmaceutical OperationsMore ExecutivesKey CompetitorsFortress BiotechNASDAQ:FBIOEmergent BioSolutionsNYSE:EBSRegulus TherapeuticsNASDAQ:RGLSNextCureNASDAQ:NXTCApollomicsNASDAQ:APLMView All CompetitorsInsiders & InstitutionsBoard of Trustees of The Leland Stanford Junior UniversitySold 37,551 shares on 2/15/2024Ownership: 1.895%Vivo Capital LLCSold 350,000 shares on 2/7/2024Ownership: 9.274%William P QuinnBought 7,500 shares on 12/12/2023Total: $7,125.00 ($0.95/share)William P QuinnBought 2,500 shares on 12/6/2023Total: $1,950.00 ($0.78/share)Edgar EnglemanSold 25,805 sharesTotal: $23,482.55 ($0.91/share)View All Insider TransactionsView All Institutional Transactions BOLT Stock Analysis - Frequently Asked Questions Should I buy or sell Bolt Biotherapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BOLT shares. View BOLT analyst ratings or view top-rated stocks. What is Bolt Biotherapeutics' stock price target for 2024? 2 analysts have issued 12 month price objectives for Bolt Biotherapeutics' stock. Their BOLT share price targets range from $6.00 to $8.00. On average, they predict the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 483.3% from the stock's current price. View analysts price targets for BOLT or view top-rated stocks among Wall Street analysts. How have BOLT shares performed in 2024? Bolt Biotherapeutics' stock was trading at $1.12 on January 1st, 2024. Since then, BOLT stock has increased by 7.1% and is now trading at $1.20. View the best growth stocks for 2024 here. Are investors shorting Bolt Biotherapeutics? Bolt Biotherapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,080,000 shares, an increase of 5.6% from the March 31st total of 1,970,000 shares. Based on an average daily volume of 128,400 shares, the days-to-cover ratio is currently 16.2 days. Approximately 8.6% of the company's stock are sold short. View Bolt Biotherapeutics' Short Interest. When is Bolt Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our BOLT earnings forecast. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.47) EPS for the quarter, meeting the consensus estimate of ($0.47). The firm earned $2.09 million during the quarter, compared to analyst estimates of $1.97 million. Bolt Biotherapeutics had a negative net margin of 878.58% and a negative trailing twelve-month return on equity of 51.18%. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP). When did Bolt Biotherapeutics IPO? Bolt Biotherapeutics (BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BOLT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
